anti-CD47 mAb (Hangzhou Sumgen Biotechnology/Zhongsheng Sumgen Biotechnology)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug Nameanti-CD47 mAb (Hangzhou Sumgen Biotechnology/Zhongsheng Sumgen Biotechnology)
Drug Alias Namerecombinant SIRPalpha fusion protein (Hangzhou Sumgen Biotechnology)CD47 checkpoint inhibitor (Hangzhou Sumgen Biotechnology/Zhongsheng Sumgen Biotechnology)SG-404 (Hangzhou Sumgen)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionImmunostimulantsCluster of differentiation 47 inhibitorsMacrophages stimulants
TargetsCluster of differentiation 47
Therapy Area/IndicationsSolid tumoursHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesZhongsheng Shangjian Biological Medicine (Hangzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesZhongsheng Shangjian Biological Medicine (Hangzhou) Co LtdHangzhou Shangjian Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursHematologic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A